Geòrgia Anguera

648 total citations
43 papers, 281 citations indexed

About

Geòrgia Anguera is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Geòrgia Anguera has authored 43 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Geòrgia Anguera's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (7 papers) and Renal cell carcinoma treatment (6 papers). Geòrgia Anguera is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (7 papers) and Renal cell carcinoma treatment (6 papers). Geòrgia Anguera collaborates with scholars based in Spain, France and United States. Geòrgia Anguera's co-authors include Pablo Maroto, Ivana Sullivan, Margarita Majem, Agustí Barnadas, Mariona Riudavets, Cristina Martín, Pablo Gallardo, Juan María Roldán‐Romero, Cristina Rodríguez‐Antona and Cristina Montero‐Conde and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Geòrgia Anguera

34 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Geòrgia Anguera Spain 11 136 116 76 48 37 43 281
Charuwan Akewanlop Thailand 9 181 1.3× 58 0.5× 51 0.7× 54 1.1× 69 1.9× 34 330
Federica Pecci Italy 12 285 2.1× 181 1.6× 98 1.3× 95 2.0× 57 1.5× 61 442
Sarah Caulfield United States 11 235 1.7× 163 1.4× 61 0.8× 36 0.8× 66 1.8× 42 353
B. Escudier France 9 94 0.7× 221 1.9× 189 2.5× 120 2.5× 48 1.3× 41 327
Guillaume Beinse France 12 125 0.9× 93 0.8× 138 1.8× 160 3.3× 41 1.1× 33 361
Haizhu Chen China 10 149 1.1× 83 0.7× 53 0.7× 46 1.0× 22 0.6× 45 281
William Leslie United States 7 208 1.5× 98 0.8× 38 0.5× 54 1.1× 36 1.0× 17 314
Taketoshi Nara Japan 10 78 0.6× 151 1.3× 83 1.1× 64 1.3× 43 1.2× 42 277
Gökhan Uçar Türkiye 11 136 1.0× 83 0.7× 28 0.4× 55 1.1× 44 1.2× 42 254
Adithya Chennamadhavuni United States 7 344 2.5× 121 1.0× 85 1.1× 35 0.7× 41 1.1× 18 446

Countries citing papers authored by Geòrgia Anguera

Since Specialization
Citations

This map shows the geographic impact of Geòrgia Anguera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Geòrgia Anguera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Geòrgia Anguera more than expected).

Fields of papers citing papers by Geòrgia Anguera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Geòrgia Anguera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Geòrgia Anguera. The network helps show where Geòrgia Anguera may publish in the future.

Co-authorship network of co-authors of Geòrgia Anguera

This figure shows the co-authorship network connecting the top 25 collaborators of Geòrgia Anguera. A scholar is included among the top collaborators of Geòrgia Anguera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Geòrgia Anguera. Geòrgia Anguera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ochsenreither, Sebastian, Geòrgia Anguera, Sebastian M. Dieter, et al.. (2025). Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. Journal of Clinical Oncology. 43(16_suppl). 2639–2639.
2.
Alonso‐Gordoa, Teresa, Geòrgia Anguera, Òscar Reig, et al.. (2025). Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews. 136. 102925–102925. 1 indexed citations
3.
Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations
4.
Anguera, Geòrgia, Mariona Riudavets, Carlos Zamora, et al.. (2024). Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 16(9). 1759–1759. 5 indexed citations
5.
Anguera, Geòrgia, Carlos Zamora, Laura Martínez‐Martínez, et al.. (2022). Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. International Journal of Molecular Sciences. 23(20). 12641–12641. 11 indexed citations
6.
Cantó, Elisabet, Ó. Rodríguez Faba, Carlos Zamora, et al.. (2021). Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy. Biomedicines. 9(9). 1125–1125. 2 indexed citations
7.
Santos, María, Javier Lanillos, Juan María Roldán‐Romero, et al.. (2021). Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Genetics in Medicine. 23(4). 698–704. 13 indexed citations
8.
Maroto, Pablo, Geòrgia Anguera, Eduardo Caleiras, et al.. (2020). mTOR pathway alterations in chromophobe renal cell carcinoma: Impact on metastasis development and overall survival.. Journal of Clinical Oncology. 38(6_suppl). 712–712.
9.
Roldán‐Romero, Juan María, María Santos, Javier Lanillos, et al.. (2020). Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Modern Pathology. 33(12). 2580–2590. 34 indexed citations
10.
Riudavets, Mariona, Joaquín Mosquera, Rosario García‐Campelo, et al.. (2020). Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Frontiers in Oncology. 10. 1677–1677. 41 indexed citations
11.
Serra, J. M., et al.. (2019). P1.07-09 Implementation of a Nursing Program for Cancer Patients Treated with Immunotherapy by an Immunotherapy Nurse Specialist. Journal of Thoracic Oncology. 14(10). S490–S491. 2 indexed citations
12.
Riudavets, Mariona, Joaquín Mosquera, Rosario García Campelo, et al.. (2019). P2.04-52 Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S728–S728. 4 indexed citations
13.
Anguera, Geòrgia, et al.. (2017). P3.02c-080 The Beneficial Effect of Platelet Binding to Monocytes on the Clinical Response to Checkpoint Inhibitors. Journal of Thoracic Oncology. 12(1). S1326–S1326.
14.
Anguera, Geòrgia, et al.. (2017). A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review. Melanoma Research. 28(2). 79–81. 1 indexed citations
15.
Anguera, Geòrgia, Miguel Ángel Molina‐Vila, Juan Ramón Gras-Cabrerizo, et al.. (2016). Molecular analysis in serial biopsies in sinonasal mucosal melanoma. Annals of Oncology. 27. vi346–vi346.
16.
Anguera, Geòrgia, Ariadna Tibau, Fernando Andrés‐Pretel, et al.. (2015). 1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer. European Journal of Cancer. 51. S176–S177. 1 indexed citations
17.
Schwartz, Deborah E., et al.. (2000). [Research on cancer localizations associated with tobacco and alcohol factors in man].. PubMed. 44(2). 336–61.
18.
Schwartz, David E., Geòrgia Anguera, & J Lenègre. (1998). [Tobacco and coronary atherosclerosis. Study of 956 cases and 956 controls].. PubMed. 6. 645–56.
19.
Schwartz, Daniel, et al.. (1966). Tobacco and other factors in the etiology of ischemic heart disease in man Results of a retrospective survey. Journal of Chronic Diseases. 19(1). 35–55. 10 indexed citations
20.
Schwartz, Daniel, et al.. (1965). Tabac et autres facteurs étiologiques dans l'artériopathie oblitérante des membres inférieurs. résultats d'une enquête rétrospective. Journal of Atherosclerosis Research. 5(3). 302–310. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charuwan Akewanlop Breakdown of academic impact, for papers by Federica Pecci Breakdown of academic impact, for papers by Sarah Caulfield Breakdown of academic impact, for papers by B. Escudier Breakdown of academic impact, for papers by Guillaume Beinse Breakdown of academic impact, for papers by Haizhu Chen Breakdown of academic impact, for papers by William Leslie Breakdown of academic impact, for papers by Taketoshi Nara Breakdown of academic impact, for papers by Gökhan Uçar Breakdown of academic impact, for papers by Adithya Chennamadhavuni
Rankless by CCL
2026